BeiGene CEO touts 'strategic asset' in flagship US site and a fix to stock delisting risk

URLhttps://www.fiercepharma.com/manufacturing/beigene
SourceFierce Pharma
Date Published04/29/2022
Author NameAngus Liu
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name BeiGene
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):100
Year reshoring announced:2022
Year reshoring implemented or to be implemented:2023
Domestically, the work will be done:In-house
Country(ies) from which reshored:China
City reshored to:Princeton
State(s) reshored to:NJ
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredbiologics, pharma
What non-domestic negative factors made offshoring less attractive?Supply chain interruption risk/Natural disaster risk/Political instability
What domestic positive factors made reshoring more attractive?Proximity to customers/market, covid-19
Find Reshoring Articles